New Collaboration Builds On Recent Malaria Antigen Discovery

In a bid to further diversify the range of options available to malaria vaccine scientists, the PATH Malaria Vaccine Initiative (MVI) and the Seattle Biomedical Research Institute (SBRI) today announced a collaboration that will place previously unused parts of the malaria parasite in the hands of vaccine developers.

More: continued here

Filed under: Tropical on March 13th, 2009